CMBA
EDIT icon

C.M. Bidwell & Associates’s Editas Medicine EDIT Stock Holding History

C.M. Bidwell & Associates’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,630
Closed -$49.9K – 525
2022
Q4 		$49.9K Buy
+5,630
New +$61.8K 0.04% 289
2022
Q1 		– Sell
-1,445
Closed -$38K – 556
2021
Q4 		$38K Buy
+1,445
New +$49.7K 0.02% 323

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

C.M. Bidwell & Associates's EDIT Position: Q1 2023 in Review

C.M. Bidwell & Associates sold out of Editas Medicine (EDIT) in Q1 2023, closing a stake of 5,630 shares — an estimated $49.9K sold.

C.M. Bidwell & Associates first reported a position in EDIT in Q4 2021 and held it in 2 quarters. The position peaked at $49.9K in Q4 2022. 234 funds tracked by Wall St. Rank hold EDIT as of Q1 2023.

  • C.M. Bidwell & Associates reported no remaining Editas Medicine position as of Q1 2023 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 5,630 Editas Medicine shares in Q1 2023, an estimated $49.9K.
  • C.M. Bidwell & Associates first reported a position in Editas Medicine in Q4 2021 and held it in 2 quarters.
  • C.M. Bidwell & Associates's Editas Medicine position peaked at $49.9K in Q4 2022.
  • 234 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2023, filed 12 May 2023.